Strategic Execution and Clinical Validation
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Initiated a rolling NDA submission for D-PLEX100 in abdominal colorectal surgery, completing CMC and nonclinical modules with clinical components expected imminently.
Advanced U.S. commercial partnership discussions to late-stage negotiations, shifting focus from due diligence to finalizing definitive agreement terms.
Strengthened the clinical value proposition with new SHIELD II data showing a 64% relative risk reduction in clinically significant wound infection severity.
Positioned D-PLEX100 to align with Medicare’s new TEAM reimbursement model, which holds hospitals financially accountable for complications within a 30-day post-surgery window.
Leveraged Breakthrough Therapy Designation to maintain frequent communication with the FDA regarding CMC processes and development reports prior to formal submission.
Maintained operational continuity and manufacturing readiness despite regional conflict, noting that the FDA has recently inspected other Israeli facilities.
Regulatory Milestones and Launch Preparation
Anticipates a potential 6-month priority review period if granted by the FDA, which would shorten the standard 10-month review timeline.
Plans to submit a Marketing Authorization Application (MAA) to the EMA in Q3 2026 following alignment meetings with European regulators.
Targets a formal U.S. commercial launch in the first quarter of 2027, supported by a strategic partner with established hospital sales infrastructure.
Expects current cash resources to fund operations into the second half of 2026, covering several significant upcoming milestones.
Prepares for a critical FDA pre-approval inspection of the internal manufacturing facility, supported by multiple successful mock audits and external consultants.
Financial and Structural Developments
Received a $4.3 million PDUFA fee waiver from the FDA under small business provisions, preserving capital for commercialization activities.
Achieved a debt-free balance sheet following the full repayment of the remaining 2022 loan facility in early May 2026.
Reported a narrowed net loss of $7.7 million for Q1 2026, down from $8.3 million in the prior year period, reflecting the completion of Phase III trials.
Analyst Q&A Session
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Confidence in CMC module and manufacturing inspection readiness
Management emphasized that owning their manufacturing facility provides full control over QA and processes, unlike relying on a CMO.
Mock inspections identified only minor comments that have already been addressed or are currently being implemented.
The company utilized Breakthrough Therapy status to align with the FDA on risky CMC aspects well before the actual filing.
finance.yahoo.com
#PolyPid #Earnings #Call #Summary
